292 lines
51 KiB
Text
292 lines
51 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-part">
|
|
<meta name="ncbi_acc" content="NBK547906">
|
|
<meta name="ncbi_domain" content="livertox">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK547906/?report=reader">
|
|
<meta name="ncbi_pagename" content="Inotuzumab Ozogamicin - LiverTox - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="chapter">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>Inotuzumab Ozogamicin - LiverTox - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="auto">
|
|
<meta name="jr-prev-unit" content="/books/n/livertox/Infliximab/?report=reader">
|
|
<meta name="jr-next-unit" content="/books/n/livertox/Insulin/?report=reader">
|
|
<meta name="bk-toc-url" content="/books/n/livertox/?report=toc">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE">
|
|
<meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]">
|
|
<meta name="citation_title" content="Inotuzumab Ozogamicin">
|
|
<meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases">
|
|
<meta name="citation_date" content="2024/01/15">
|
|
<meta name="citation_pmid" content="31643242">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK547906/">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="Inotuzumab Ozogamicin">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases">
|
|
<meta name="DC.Date" content="2024/01/15">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK547906/">
|
|
<meta name="description" content="Inotuzumab ozogamicin is a humanized monoclonal antibody-cytotoxin conjugate which is used in the therapy of refractory or relapsed acute lymphoblastic leukemia. Inotuzumab ozogamicin has been linked to frequent serum enzyme elevations during therapy and with instances of clinically apparent acute liver injury, including acute sinusoidal obstruction syndrome which can be severe and even fatal.">
|
|
<meta name="og:title" content="Inotuzumab Ozogamicin">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:description" content="Inotuzumab ozogamicin is a humanized monoclonal antibody-cytotoxin conjugate which is used in the therapy of refractory or relapsed acute lymphoblastic leukemia. Inotuzumab ozogamicin has been linked to frequent serum enzyme elevations during therapy and with instances of clinically apparent acute liver injury, including acute sinusoidal obstruction syndrome which can be severe and even fatal.">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK547906/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/livertox/InotuzumabOzogamicin/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK547906/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8E625A7D7DB00100000000003B0037.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK547906/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"><div class="head"><a href="/books/n/livertox/Infliximab/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="body"><div class="t">Inotuzumab Ozogamicin</div><div class="j">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</div></div><div class="tail"><a href="/books/n/livertox/Insulin/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-rtoc-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK547906/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK547906/&text=Inotuzumab%20Ozogamicin"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-rtoc-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Table of Content</div></div><div class="cnt lol f1"><a href="/books/n/livertox/?report=reader">Title Information</a><a href="/books/n/livertox/toc/?report=reader">Table of Contents Page</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK547906/?report=classic">Switch to classic view</a><a href="/books/NBK547906/pdf/Bookshelf_NBK547906.pdf">PDF (113K)</a><a href="/books/NBK547906/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK547906%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8E625A7D7DB00100000000003B0037.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><div class="fm-sec"><h1 id="_NBK547906_"><span class="title" itemprop="name">Inotuzumab Ozogamicin</span></h1><p class="fm-aai"><a href="#_NBK547906_pubdet_">Publication Details</a></p></div></div><div class="body-content whole_rhythm" itemprop="text"><div id="InotuzumabOzogamicin.OVERVIEW"><h2 id="_InotuzumabOzogamicin_OVERVIEW_">OVERVIEW</h2><div id="InotuzumabOzogamicin.Introduction"><h3>Introduction</h3><p>Inotuzumab ozogamicin is a humanized monoclonal antibody-cytotoxin conjugate which is used in the therapy of refractory or relapsed acute lymphoblastic leukemia. Inotuzumab ozogamicin has been linked to frequent serum enzyme elevations during therapy and with instances of clinically apparent acute liver injury, including acute sinusoidal obstruction syndrome which can be severe and even fatal.</p></div><div id="InotuzumabOzogamicin.Background"><h3>Background</h3><p>Inotuzumab (in" oh tooz' ue mab) ozogamicin (oh" zoe ga mye' sin) is a humanized monoclonal antibody conjugate that is used in the therapy of B-cell precursor acute lymphoblastic leukemia. The monoclonal antibody is to the human CD22 cell surface marker which is highly expressed on malignant lymphoblastic leukemia cells. The monoclonal antibody is conjugated to a cytotoxic agent from a class of calicheamicins called ozogamicin. When inotuzumab binds to CD22, it is internalized and the ozogamicin is released by the action of lysosomal enzymes on the linker molecule that joins it to the monoclonal antibody. The released intracellular ozogamicin causes breaks in double stranded DNA that leads to apoptotic cell death. This monoclonal antibody conjugate has been shown to be effective in inducing remissions in relapsed or refractory B-cell precursor acute lymphoblastic leukemia and was given accelerated approval for this indication in the United States in 2017. Inotuzumab ozogamicin is available as 0.9 mg of lyophilized powder in single dose vials for reconstitution under the brand name Besponsa. The recommended dose regimen varies by body weight, day of therapy and whether treating refractory vs relapsed acute lymphoblastic leukemia. Inotuzumab ozogamicin is given intravenously typically on days 1, 8 and 15 of 21- or 28-day cycles. Premedication with a corticosteroid, antipyretic, and antihistamine is recommended before each dose. Common side effects include bone marrow suppression, infections, fatigue, fever, nausea, headache, abdominal pain and hemorrhage. Less common but potentially serious side effects include severe myelosuppression, severe infections, clinically significant bleeding and hemorrhage, infusion related reactions including anaphylaxis, QTc interval prolongation, and embryo-fetal toxicity. Inotuzumab ozogamicin should be prescribed and administered only by health care workers with expertise and experience in cancer chemotherapy and management of its adverse events.</p></div><div id="InotuzumabOzogamicin.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>In prelicensure clinical trials of inotuzumab ozogamicin, up to half of patients had serum ALT or AST elevations during therapy which were above 5 times the upper limit of normal (ULN) in 2% to 5%. Hyperbilirubinemia was also common during inotuzumab therapy, generally occurring without accompanying ALT or AST elevations. More importantly, a variable proportion of patients (ranging from 2% to 35%) developed clinically apparent sinusoidal obstruction syndrome (SOS) after inotuzumab ozogamicin therapy. The proportion was even higher (15% to 25%) in patients who receive inotuzumab ozogamicin and subsequently underwent hematopoietic cell transplantation (HCT). Symptoms of nausea, right upper quadrant pain, weight gain and abdominal distension (from ascites) arose within 5 to 20 days of the infusion and were followed in some patients by progressive rises in bilirubin, serum aminotransferase and alkaline phosphatase levels. Clinically apparent SOS has a poor prognosis and the mortality rate is as high as 70%, most patients dying of multiorgan failure. Risk factors for developing SOS after inotuzumab therapy include allogenic hematopoietic cell transplantation, use of other antineoplastic agents, and presence of preexisting liver disease. While SOS is the usual cause of clinically apparent liver injury attributable to inotuzumab, cases of cholestatic hepatitis without evidence of sinusoidal cell injury have been described in up to 8% of treated subjects. The clinical features of this injury have not been well characterized. Patients being treated with inotuzumab ozogamicin are often receiving multiple medications and have other reasons for having acute liver injury (sepsis, shock, graft-vs-host disease, or hepatic metastases).</p><p>Likelihood score: A (well known cause of clinically apparent liver injury, generally due to sinusoidal obstruction syndrome).</p></div><div id="InotuzumabOzogamicin.Mechanism_of_Liver"><h3>Mechanism of Liver Injury</h3><p>The cause of the serum enzyme elevations during inotuzumab ozogamicin therapy is not known, but they are likely due to direct toxicity of the conjugate. The propensity of inotuzumab ozogamicin to cause sinusoidal obstruction syndrome is perhaps due to the fact that the antibody conjugate may be taken up by these cells resulting in their damage and release of cellular apoptotic fragments into sinusoids causing obstruction.</p></div><div id="InotuzumabOzogamicin.Outcome_and_Managem"><h3>Outcome and Management</h3><p>The mild-to-moderate serum aminotransferase elevations that occur during inotuzumab ozogamicin therapy are generally transient and asymptomatic and do not require dose modification or delay in therapy. Elevations above 5 times the upper limit of normal should lead to more careful monitoring and suspension of further infusions, at least until levels return to normal or near normal levels. The product label for inotuzumab ozogamicin has a black boxed warning for the risk of severe sinusoidal obstruction syndrome and recommends monitoring routine liver tests before administering each dose of the antibody-drug conjugate. Management of SOS generally rests on careful attention to fluid balance and treatment of complications. There are no proven means of prevention or treatment of SOS due to inotuzumab ozogamicin, although pretreatment with ursodiol and acute management with defibrotide are often employed. The adverse events profile and hepatotoxicity of inotuzumab ozogamicin are similar to those caused by gemtuzumab ozogamicin, a similar monoclonal antibody-conjugate directed to CD33 that is used to treat refractory or relapsed acute myeloid leukemia.</p><p>Drug Class: <a href="/books/n/livertox/AntineoplasticAgents/?report=reader">Antineoplastic Agents</a>; <a href="/books/n/livertox/MonoclonalAntibodies/?report=reader">Monoclonal Antibodies</a></p><p>Other Monoclonal Antibody Conjugates: Benlantamab Mafodotin, Brentuximab Vedotin, Enfortumab Vedotin, Gemtuzumab Ozogamicin, Polatuzumab Vedotin, Sacituzumab Govitecan, Tisotumab Vedotin, Trastuzumab Deruxtecan, Trastuzumab Emtansine</p></div></div><div id="InotuzumabOzogamicin.PRODUCT_INFORMATION"><h2 id="_InotuzumabOzogamicin_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><p>
|
|
<b>REPRESENTATIVE TRADE NAMES</b>
|
|
</p><p>Inotuzumab Ozogamicin – Besponsa®</p><p>
|
|
<b>DRUG CLASS</b>
|
|
</p><p>Antineoplastic Agents</p><p>
|
|
<a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Inotuzumab+Ozogamicin" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">COMPLETE LABELING</a>
|
|
</p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div><div id="InotuzumabOzogamicin.CHEMICAL_FORMULA_AN"><h2 id="_InotuzumabOzogamicin_CHEMICAL_FORMULA_AN_">CHEMICAL FORMULA AND STRUCTURE</h2><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figInotuzumabOzogamicinTc"><a href="/books/NBK547906/table/InotuzumabOzogamicin.Tc/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figInotuzumabOzogamicinTc" rid-ob="figobInotuzumabOzogamicinTc"><img class="small-thumb" src="/books/NBK547906/table/InotuzumabOzogamicin.Tc/?report=thumb" src-large="/books/NBK547906/table/InotuzumabOzogamicin.Tc/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="InotuzumabOzogamicin.Tc"><a href="/books/NBK547906/table/InotuzumabOzogamicin.Tc/?report=objectonly" target="object" rid-ob="figobInotuzumabOzogamicinTc">Table</a></h4></div></div></div><div id="InotuzumabOzogamicin.ANNOTATED_BIBLIOGRA"><h2 id="_InotuzumabOzogamicin_ANNOTATED_BIBLIOGRA_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 15 January 2024</p><p>Abbreviations: ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; GvH, graft-vs-host; HCT, hematopoietic cell transplantation; SOS, sinusoidal obstruction syndrome (also known as hepatic veno-occlusive disease).</p><ul class="first-line-outdent"><li><div class="bk_ref" id="InotuzumabOzogamicin.REF.deleve.2011">DeLeve LD. Gemtuzumab ozogamicin. Liver sinusoidal endothelial cells and liver injury. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2011, pp. 142-3.<div><i>(Review of agents that damage liver sinusoidal cells including gemtuzumab ozogamicin; mentions that CD33 which is present on leukemic blast cells is also present on liver sinusoidal endothelial cells).</i></div></div></li><li><div class="bk_ref" id="InotuzumabOzogamicin.REF.wellstein.2018">Wellstein A, Giaccone G, Atkins MB, Sausville EA. Pathway-targeted therapies: monoclonal antibodies, protein kinase inhibitors, and various small molecules. In, Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman & Gilman's the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 2018, pp. 1203-36.<div><i>(Textbook of pharmacology and therapeutics).</i></div></div></li><li><div class="bk_ref" id="InotuzumabOzogamicin.REF.fda">FDA. <a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761040Orig1s000MultidisciplineR.pdf" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">https://www<wbr style="display:inline-block"></wbr>​.accessdata<wbr style="display:inline-block"></wbr>​.fda.gov/drugsatfda_docs<wbr style="display:inline-block"></wbr>​/nda/2017/761040Orig1s000MultidisciplineR.pdf</a><div><i>(FDA Drug Approvals website that has product labels [package inserts], letters of approval and full FDA scientific review of the new drug application for safety and efficacy which mentions that ALT elevations occur in up to 50% of inotuzumab ozogamicin treated subjects and are above 5 times ULN in 2% to 5%, but these abnormalities are generally are self-limited and without symptoms or jaundice, but that SOS occurs in 3% of treated subjects not undergoing HCT and as many as 22% of those with HCT [before or after treatment]).</i></div></div></li><li><div class="bk_ref" id="InotuzumabOzogamicin.REF.rajvanshi.2002.2310">Rajvanshi
|
|
P, Shulman
|
|
HM, Sievers
|
|
EL, McDonald
|
|
GB. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy.
|
|
Blood
|
|
2002; 99: 2310-4.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/11895761" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11895761</span></a>]<div><i>(Among 23 patients with relapsed, refractory acute myeloid leukemia [AML] treated with gemtuzumab ozogamicin, liver injury suggestive of SOS developed in 11, 7 of whom died of hepatic failure 8-47 days after the infusion).</i></div></div></li><li><div class="bk_ref" id="InotuzumabOzogamicin.REF.leopold.2002.s29">Leopold
|
|
LH, Berger
|
|
MS, Feingold
|
|
J. Acute and long-term toxicities associated with gemtuzumab ozogamicin (Mylotarg) therapy of acute myeloid leukemia.
|
|
Clin Lymphoma
|
|
2002; 2
|
|
Suppl 1: S29-34.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/11970768" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11970768</span></a>]<div><i>(Review of adverse side effects of gemtuzumab ozogamicin therapy; mentions mild ALT and AST [Grade 1 and 2] elevations in 26% and elevations ≥5 times ULN in 16% and clinically apparent SOS in 2-12% of patients, risk factors for this complication being HCT, concurrent cytotoxic therapies, higher and more frequent doses and underlying liver disease).</i></div></div></li><li><div class="bk_ref" id="InotuzumabOzogamicin.REF.mcdonald.2002.s35">McDonald
|
|
GB. Management of hepatic sinusoidal obstruction syndrome following treatment with gemtuzumab ozogamicin (Mylotarg).
|
|
Clin Lymphoma
|
|
2002; 2
|
|
Suppl 1: S35-9.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/11970769" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11970769</span></a>]<div><i>(Review of management of SOS).</i></div></div></li><li><div class="bk_ref" id="InotuzumabOzogamicin.REF.kantarjian.2012.403">Kantarjian
|
|
H, Thomas
|
|
D, Jorgensen
|
|
J, Jabbour
|
|
E, Kebriaei
|
|
P, Rytting
|
|
M, York
|
|
S, et al.
|
|
Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study.
|
|
Lancet Oncol
|
|
2012; 13: 403-11.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/22357140" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22357140</span></a>]<div><i>(Among 49 patients with refractory or relapsed ALL treated with inotuzumab, 57% had an objective response and adverse events included fever [59%], ALT elevations [57%: all but 1 being less than 5 times ULN], hyperbilirubinemia [26%], hypotension [26%] and SOS in 5 of 22 [23%] who subsequently underwent HCT, 1 case being fatal).</i></div></div></li><li><div class="bk_ref" id="InotuzumabOzogamicin.REF.wagnerjohnston.2015.2863">Wagner-Johnston
|
|
ND, Goy
|
|
A, Rodriguez
|
|
MA, Ehmann
|
|
WC, Hamlin
|
|
PA, Radford
|
|
J, Thieblemont
|
|
C, et al.
|
|
A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma.
|
|
Leuk Lymphoma
|
|
2015; 56: 2863-9.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/25707288" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25707288</span></a>]<div><i>(Among 63 patients with relapsed or refractory large B cell lymphoma treated with inotuzumab and rituximab, the objective response rate was 29% and adverse events were common including AST elevations in 43%; 4 of 18 patients [22%] who subsequently underwent HCT developed significant hepatotoxicity, 2 with suspected SOS).</i></div></div></li><li><div class="bk_ref" id="InotuzumabOzogamicin.REF.kantarjian.2016.740">Kantarjian
|
|
HM, DeAngelo
|
|
DJ, Stelljes
|
|
M, Martinelli
|
|
G, Liedtke
|
|
M, Stock
|
|
W, Gökbuget
|
|
N, et al.
|
|
Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia.
|
|
N Engl J Med
|
|
2016; 375: 740-53.
|
|
[<a href="/pmc/articles/PMC5594743/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5594743</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27292104" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27292104</span></a>]<div><i>(Among 326 patients with refractory or relapsed ALL treated with inotuzumab ozogamicin or standard intensive chemotherapy, complete remissions were more frequent with inotuzumab [81% vs 29%] and medial overall survival was greater [7.7 vs 6.7 months], and while adverse events were frequent in both groups, SOS occurred in 11% [including 2 fatal cases following HCT] with inotuzumab vs 1% with standard therapy).</i></div></div></li><li><div class="bk_ref" id="InotuzumabOzogamicin.REF.kantarjian.2016.2100">Kantarjian
|
|
HM, Vandendries
|
|
E, Advani
|
|
AS. Inotuzumab ozogamicin for acute lymphoblastic leukemia.
|
|
N Engl J Med
|
|
2016; 375: 2100-2101.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/27959720" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27959720</span></a>]<div><i>(Further follow up of patients in a controlled trial [Kantarjian 2016] mentions that 15 of 71 patients [21%] who underwent HCT after receipt of inotuzumab for ALL developed SOS, and that there was no correlation between time after receipt of the agent and frequency of SOS).</i></div></div></li><li><div class="bk_ref" id="InotuzumabOzogamicin.REF.goy.2016.571">Goy
|
|
A, Forero
|
|
A, Wagner-Johnston
|
|
N, Christopher Ehmann
|
|
W, Tsai
|
|
M, Hatake
|
|
K, Ananthakrishnan
|
|
R, et al.
|
|
A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy.
|
|
Br J Haematol
|
|
2016; 174: 571-81.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/27101934" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27101934</span></a>]<div><i>(Among 81 patients with refractory non-Hodgkin lymphoma treated with inotuzumab ozogamicin, the objective response rate was 67% and adverse events were common including thrombocytopenia [74%], neutropenia [56%], anemia [15%], ALT elevations [20%: only 1 rising above 5 times ULN] and hyperbilirubinemia [15%]).</i></div></div></li><li><div class="bk_ref" id="InotuzumabOzogamicin.REF.kantarjian.2017.e387">Kantarjian
|
|
HM, DeAngelo
|
|
DJ, Advani
|
|
AS, Stelljes
|
|
M, Kebriaei
|
|
P, Cassaday
|
|
RD, Merchant
|
|
AA, et al.
|
|
Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study.
|
|
Lancet Haematol
|
|
2017; 4: e387-e398.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/28687420" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28687420</span></a>]<div><i>(Secondary analysis of liver related adverse events in a large controlled trial of inotuzumab vs placebo [Kantarjian 2016], with follow up data on all 326 patients enrolled, reported elevations in ALT in 15% vs 13%, AST in 23% vs 11%, Alk P in 13% vs 7%, bilirubin in 21% vs 17% and SOS in 13% [n=22, 5 fatal] vs <1% with SOS occurring without intervening HCT in 5 [3%] vs none).</i></div></div></li><li><div class="bk_ref" id="InotuzumabOzogamicin.REF.dang.2018.583">Dang
|
|
NH, Ogura
|
|
M, Castaigne
|
|
S, Fayad
|
|
LE, Jerkeman
|
|
M, Radford
|
|
J, Pezzutto
|
|
A, et al.
|
|
Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
|
|
Br J Haematol
|
|
2018; 182 (4): 583-6.
|
|
[<a href="/pmc/articles/PMC6200343/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6200343</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28677896" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28677896</span></a>]<div><i>(Among 332 patients with non-Hodgkin lymphoma treated with rituximab combined with inotuzumab ozogamicin or with standard chemotherapy, overall survival was similar in the two groups while adverse events were more frequent with inotuzumab including elevations in ALT [17% vs 8%], Alk P [13% vs 5%], bilirubin [8% vs 2%] and SOS [2% vs none]).</i></div></div></li><li><div class="bk_ref" id="InotuzumabOzogamicin.REF.lamb.2017.1603">Lamb
|
|
YN. Inotuzumab ozogamicin: first global approval.
|
|
Drugs
|
|
2017; 77: 1603-10.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/28819740" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28819740</span></a>]<div><i>(Review of the history of development, mechanism of action, pharmacology, clinical efficacy and safety of inotuzumab ozogamicin shortly after its approval in the US; mentions that cases of SOS were more frequent with inotuzumab than standard therapy [13% vs 1%], some cases arising years after its administration, often after HCT).</i></div></div></li><li><div class="bk_ref" id="InotuzumabOzogamicin.REF.kantarjian.2018.240">Kantarjian
|
|
H, Ravandi
|
|
F, Short
|
|
NJ, Huang
|
|
X, Jain
|
|
N, Sasaki
|
|
K, Daver
|
|
N, et al.
|
|
Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study.
|
|
Lancet Oncol
|
|
2018; 19: 240-8.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/29352703" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29352703</span></a>]<div><i>(Among 52 elderly patients [60 years or older] with newly diagnosed ALL treated with inotuzumab ozogamicin and low intensity standard chemotherapy, almost all patients had an objective response, and all had hepatic adverse events including SOS in 4 patients [8%], 2 of which were fatal, 1 occurring after HCT).</i></div></div></li><li><div class="bk_ref" id="InotuzumabOzogamicin.REF.jabbour.2018.230">Jabbour
|
|
E, Ravandi
|
|
F, Kebriaei
|
|
P, Huang
|
|
X, Short
|
|
NJ, Thomas
|
|
D, Sasaki
|
|
K, et al.
|
|
Salvage chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD for patients with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: a phase 2 clinical trial.
|
|
JAMA Oncol
|
|
2018; 4: 230-4.
|
|
[<a href="/pmc/articles/PMC5838597/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5838597</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28859185" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28859185</span></a>]<div><i>(Among 59 patients with relapsed or refractory ALL treated with inotuzumab and lower dose standard chemotherapy, the overall objective response rate was 78%, while 95% had at least one hepatic adverse event and 9 [15%] developed SOS, all of whom had received HCT either before or after inotuzumab therapy).</i></div></div></li><li><div class="bk_ref" id="InotuzumabOzogamicin.REF17">Inotuzumab ozogamicin (Besponsa)--an antibody-drug conjugate for ALL.
|
|
Med Lett Drugs Ther
|
|
2018; 60 (1547): e90-e91.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/29913470" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29913470</span></a>]<div><i>(Concise review of the mechanism of action, clinical efficacy, safety and costs of inotuzumab ozogamicin, shortly after its approval as therapy of refractory or relapsed, B-cell precursor ALL in adults, mentions that SOS occurred in 18 of 79 patients [23%] treated with inotuzumab who subsequently underwent HCT, the mortality rate of which was 28%).</i></div></div></li><li><div class="bk_ref" id="InotuzumabOzogamicin.REF.mcdonald.2019.831">McDonald
|
|
GB, Freston
|
|
JW, Boyer
|
|
JL, DeLeve
|
|
LD. Liver complications following treatment of hematologic malignancy with anti-CD22-calicheamicin (inotuzumab ozogamicin).
|
|
Hepatology.
|
|
2019;69:831-844.
|
|
[<a href="/pmc/articles/PMC6351187/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6351187</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30120894" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30120894</span></a>]<div><i>(Expert analysis of liver injury in two large controlled trials of trastuzumab ozogamicin vs standard care in 628 adults with ALL identified SoS in 1.5% vs none and drug induced liver injury in 8% vs 1%).</i></div></div></li><li><div class="bk_ref" id="InotuzumabOzogamicin.REF.corbacioglu.2019.1271">Corbacioglu
|
|
S, Jabbour
|
|
EJ, Mohty
|
|
M. Risk factors for development of and progression of hepatic veno-occlusive disease/sinusoidal obstruction syndrome.
|
|
Biol Blood Marrow Transplant.
|
|
2019;25:1271-1280.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/30797942" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30797942</span></a>]<div><i>(Systematic review of the risk factors for development of SOS after HCT identified gemtuzumab ozogamicin and inotuzumab ozogamicin as having hazard risk odds ratios of 20 and 22).</i></div></div></li><li><div class="bk_ref" id="InotuzumabOzogamicin.REF.kantarjian.2019.2474">Kantarjian
|
|
HM, DeAngelo
|
|
DJ, Stelljes
|
|
M, Liedtke
|
|
M, Stock
|
|
W, Gökbuget
|
|
N, O'Brien
|
|
SM, et al.
|
|
Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study.
|
|
Cancer.
|
|
2019;125: 2474-2487.
|
|
[<a href="/pmc/articles/PMC6618133/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6618133</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30920645" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30920645</span></a>]<div><i>(Among 326 adults with refractory or relapsed ALL treated with inotuzumab ozogamicin or standard chemotherapy and followed for 2 years or more, the complete remission rate was 74% vs 31%, and the 2-year overall survival rate was 23% vs 10%, although SOS occurred in 14% vs 2%).</i></div></div></li><li><div class="bk_ref" id="InotuzumabOzogamicin.REF.agrawal.2023.314">Agrawal
|
|
V, Pourhassan
|
|
H, Tsai
|
|
NC, Ngo
|
|
D, Koller
|
|
P, Malki
|
|
MMA, Salhotra
|
|
A, et al.
|
|
Post-transplantation sinusoidal obstruction syndrome in adult patients with B cell acute lymphoblastic leukemia treated with pretransplantation inotuzumab.
|
|
Transplant Cell Ther.
|
|
2023;29:314-320.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/36682470" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 36682470</span></a>]<div><i>(Among 47 adults with refractory or relapsed ALL who received inotuzumab ozogamicin and subsequently underwent HCT, 12 [26%] developed SOS which was severe in 9 and fatal in 4).</i></div></div></li><li><div class="bk_ref" id="InotuzumabOzogamicin.REF.lee.2021.20406207211066176">Lee
|
|
J, Yoon
|
|
JH, Kwag
|
|
D, Lee
|
|
JH, Kim
|
|
TY, Min
|
|
GJ, Park
|
|
SS, et al.
|
|
Hepatic venoocclusive disease/sinusoidal obstruction syndrome with normal portal vein flow mimicking aggravated chronic hepatic GVHD following inotuzumab ozogamicin salvage therapy: a case report of pathologic-radiologic discrepancy.
|
|
Ther Adv Hematol.
|
|
2021;12:20406207211066176.
|
|
[<a href="/pmc/articles/PMC8721405/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC8721405</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34987745" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 34987745</span></a>]<div><i>(49 year old woman with relapse of ALL 2 years after a successful HCT and with chronic graft-vs-host [GvH] disease was treated with inotuzumab ozogamicin and developed progressive hepatic failure that led to a liver transplant, the explant showing SOS rather than GvH disease).</i></div></div></li><li><div class="bk_ref" id="InotuzumabOzogamicin.REF.sabatino.2023.840">Sabatino
|
|
D, Henneman
|
|
A, Ahmad
|
|
S, Jou
|
|
E, Goldberg
|
|
B. Evaluation of the efficacy of ursodiol for prevention of hepatotoxicity in patients receiving gemtuzumab ozogamicin and inotuzumab ozogamicin.
|
|
J Oncol Pharm Pract.
|
|
2023;29:840-845.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/35293248" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 35293248</span></a>]<div><i>(In a retrospective analysis of patients who received gemtuzumab or inotuzumab ozogamicin with [n=14] or without ursodiol [n=35] prophylaxis, the rate of SOS was less with ursodiol [14% vs 43%], but after controlling for risk factors the difference was not statistically significant).</i></div></div></li><li><div class="bk_ref" id="InotuzumabOzogamicin.REF.fischer.2024.489">Fischer
|
|
D, Toenges
|
|
R, Kiil
|
|
K, Michalik
|
|
S, Thalhammer
|
|
A, Bug
|
|
G, Gökbuget
|
|
N, Lang
|
|
F. Liver failure after treatment with inotuzumab and polychemotherapy including PEG-asparaginase in a patient with relapsed Philadelphia chromosome-negative acute lymphoblastic leukemia.
|
|
Ann Hematol.
|
|
2024;103(2):489-498.
|
|
[<a href="/pmc/articles/PMC10798915/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC10798915</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37999763" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 37999763</span></a>]<div><i>(58 year old woman with relapsed ALL after HCT was treated with inotuzumab ozogamicin followed by methotrexate and pegaspargase and developed fatal acute liver failure 2 weeks later, autopsy showing steatosis and cholestasis typical of asparaginase induced injury, but no evidence of SOS).</i></div></div></li><li><div class="bk_ref" id="InotuzumabOzogamicin.REF.sun.2023.1">Sun
|
|
C, Yang
|
|
X, Tang
|
|
L, Chen
|
|
J.
|
|
A pharmacovigilance study on drug-induced liver injury associated with antibody-drug conjugates (ADCs) based on the food and drug administration adverse event reporting system.
|
|
Expert Opin Drug Saf.
|
|
2023:1-12.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/37898875" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 37898875</span></a>]<div><i>(Analysis of the FDA reporting system [FAERS] for cases of drug induced liver injury submitted between 2004 and 2022, found 17,784 reports, 504 [3%] attributed to antibody-drug conjugates, 202 from the US, the implicated agents being gemtuzumab ozogamicin [n=98], brentuximab vedotin [n=37], trastuzumab emtansine [n=25], enfortumab vedotin [n=16], inotuzumab ozogamicin [n=15], transtuzumab deruxtecan [n=8], and polatuzumab vedotin [3]).</i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div><div class="fm-sec"><h2 id="_NBK547906_pubdet_">Publication Details</h2><h3>Publication History</h3><p class="small">Last Update: <span itemprop="dateModified">January 15, 2024</span>.</p><h3>Copyright</h3><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div></div><h3>Publisher</h3><p><a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&targetsite=external&targetcat=link&targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>, Bethesda (MD)</p><h3>NLM Citation</h3><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Inotuzumab Ozogamicin. [Updated 2024 Jan 15].<span class="bk_cite_avail"></span></p></div><div class="small-screen-prev"><a href="/books/n/livertox/Infliximab/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="small-screen-next"><a href="/books/n/livertox/Insulin/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></article><article data-type="table-wrap" id="figobInotuzumabOzogamicinTc"><div id="InotuzumabOzogamicin.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK547906/table/InotuzumabOzogamicin.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__InotuzumabOzogamicin.Tc_lrgtbl__"><table><thead><tr><th id="hd_h_InotuzumabOzogamicin.Tc_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DRUG</th><th id="hd_h_InotuzumabOzogamicin.Tc_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CAS REGISTRY NUMBER</th><th id="hd_h_InotuzumabOzogamicin.Tc_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_InotuzumabOzogamicin.Tc_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_InotuzumabOzogamicin.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Inotuzumab Ozogamicin</td><td headers="hd_h_InotuzumabOzogamicin.Tc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/135298753" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">635715-01-4</a>
|
|
</td><td headers="hd_h_InotuzumabOzogamicin.Tc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Monoclonal Antibody</td><td headers="hd_h_InotuzumabOzogamicin.Tc_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not Available</td></tr></tbody></table></div></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal107 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|